evidence table

Berberine Blood Pressure Randomized Trial Evidence Table

Name: Berberine Blood Pressure Randomized Trial Evidence Table
Creator: Migaku
License: https://creativecommons.org/licenses/by/4.0/

Structured evidence table for Berberine Blood Pressure Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.

topic	claim	evidence level	citation	source
Berberine Blood Pressure Randomized Trial	Objectives To evaluate the efficacy and safety of berberine in reducing VAT area and liver fat content in diabetes-free individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).	2	Lei L (2026)	Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.
Berberine Blood Pressure Randomized Trial	Berberine was associated with larger reductions in low-density lipoprotein cholesterol (-7.72 [95% CI, -13.13 to -1.93] mg/dL), apolipoprotein B (-3.42 [95% CI, -6.33 to -0.51] mg/dL) and high-sensitivity C-reactive protein (hs-CRP) (-0.072 [95% CI, -0.140 to -0.004] mg/dL) vs placebo, but not other secondary outcomes.	2	Lei L (2026)	Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.
Berberine Blood Pressure Randomized Trial	Importance Berberine is a potential therapy for metabolic disorders, yet its effects on visceral adipose tissue (VAT) and liver fat remain uncertain.	2	Lei L (2026)	Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.

Source documents